A Phase 1 interventional study of CPTX2309 and CPTX2309 in Healthy Volunteers, Rheumatoid Arthritis and Systemic Lupus Erythematosus, sponsored by Capstan Therapeutics. Recruiting at 3 sites in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-16.
Sponsored by Capstan Therapeutics (part of AbbVie) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies in Arthritis, Rheumatoid by AbbVie — 5 open to participants now, 6 under way, 1 of them phase 3. Arthritis, Rheumatoid · AbbVie.
Among the 80 studies in Arthritis, Rheumatoid by AbbVie, this one is the 30th largest by planned enrollment of the 38 interventional ones that give a count, is one of 2 that started in 2025, is one of 6 in phase 1, and was the 77th registered.
3,336 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →5 of the 80 studies in Arthritis, Rheumatoid by AbbVie are open now, in 12 countries. Recruiting first, the newest first:
AbbVie · Sites in United States, Japan
Ages 18–75
AbbVie · Sites in United States, Canada, Czechia and 9 more countries
Ages 18+
AbbVie · Sites in Germany
Ages 18+
AbbVie
Ages 18+
By country, each count listing its studies:
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 17 · Phase 3 12 · Phase 4 4
First in 2000; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 64 is below the median of 96 across 2,223 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 210 across the 38 interventional studies, 401 across the 41 observational. Of the 71 that completed or were terminated, 54 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Capstan Therapeutics, one of the names counted as AbbVie. Under that name alone:
This is the only study on the registry with Capstan Therapeutics as lead sponsor.
2 of the studies in Arthritis, Rheumatoid by AbbVie that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06972446AbbVieA Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis | 2027-02 |
| NCT06917742Capstan TherapeuticsA Study of Intravenous CPTX2309 in Healthy Participants and Participants With Moderate to Severe Rheumatoid Arthritis (RA) or Systemic Lupus Erythematosus (SLE) | 2027-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 80 studies in Arthritis, Rheumatoid by AbbVie, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety and tolerability of CPTX2309 in healthy adult participants and adult participants with moderate to severe rheumatoid arthritis or systemic lupus erythematosus.
A first-in-human Phase 1, open label study to evaluate safety and tolerability of a single ascending dose (SAD) and multiple ascending dose (MAD) of CPTX2309 intravenously administered to healthy adult participants and adult participants with moderate to severe rheumatoid arthritis or systemic lupus erythematosus.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
RA Only:
SLE Only:
Exclusion Criteria:
RA Only:
- Participants diagnosed with Felty's syndrome
SLE Only:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Escalating single doses of CPTX2309 on a specified day to healthy adult participants.
Drug: CPTX2309
Escalating multiple doses of CPTX2309 on specified days to healthy adult participants.
Drug: CPTX2309
Escalating single doses of CPTX2309 on a specified day to adult participants with moderate to severe RA or SLE.
Drug: CPTX2309
Escalating multiple doses of CPTX2309 on specified days to adult participants with moderate to severe RA or SLE.
Drug: CPTX2309
Intravenous Infusion
Intravenous Infusion
Number of participants with changes in the safety parameters
To evaluate the safety and tolerability of CPTX2309 administered to healthy adult participants and participants with moderate to severe RA and SLE.
Time frame: Up to approximately 1 Year
Number of participants with clinical laboratory assessment abnormalities
To evaluate the safety and tolerability of CPTX2309 administered to healthy adult participants and participants with moderate to severe RA and SLE.
Time frame: Up to approximately 1 Year
Number of participants with changes in the vital signs
To evaluate the safety and tolerability of CPTX2309 administered to healthy adult participants and participants with moderate to severe RA and SLE.
Time frame: Up to approximately 1 Year
Number of participants with changes in the ECG
To evaluate the safety and tolerability of CPTX2309 administered to healthy adult participants and participants with moderate to severe RA and SLE.
Time frame: Up to approximately 1 Year
Number of participants who develop anti-drug antibodies (ADAs) and Circulating Immune Complex (CIC) formation
To evaluate the safety and tolerability of CPTX2309 administered to healthy adult participants and participants with moderate to severe RA and SLE.
Time frame: Up to approximately 1 Year
Part A and B: Number of participants with change from baseline in vaccine antibody titers
To evaluate the safety and tolerability of CPTX2309 administered to healthy adult participants.
Time frame: Up to approximately 1 Year
Changes in serum cytokine and chemokine levels that are known to be associated with CAR-T cell therapy related toxicity
To evaluate the safety and tolerability of CPTX2309 administered to healthy adult participants and participants with moderate to severe RA and SLE.
Time frame: Up to approximately 1 Year
Change from baseline in soluble immunoglobulins (Ig)
To evaluate the safety and tolerability of CPTX2309 administered to healthy adult participants and participants with moderate to severe RA and SLE.
Time frame: Up to approximately 1 Year
Part C and D: Change from baseline in vaccination-induced antibody titers
To evaluate the safety and tolerability of CPTX2309 administered to participants with moderate to severe RA and SLE.
Time frame: Up to approximately 1 Year
Pharmacokinetic Parameters
Levels of CAR+ T cells, levels of CPTX2309 components
Time frame: Up to approximately 1 Year
Pharmacodynamic Parameters
Levels of circulating B cells expressed as the number of CD19 positive B cells in one microliter of blood by flow cytometry
Time frame: Up to approximately 1 Year
Part A and B: Pharmacodynamic Parameters
Percentages of naïve and memory B cells in blood by flow cytometry
Time frame: Up to approximately 1 Year
Part A and B: Pharmacodynamic Parameters
Levels of cytokines and chemokines in nanograms per milliliter of serum by ELISA
Time frame: Up to approximately 1 Year
Part C and D: Number of Participants who develop ADAs
To evaluate the PK profile of CPTX2309 in participants with moderate to severe RA or SLE.
Time frame: Up to approximately 1 Year
Not enrolling at this site.
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2025 (actual). Primary completion is estimated for Nov 2027, 31 months after the start.
Of 128 industry-sponsored phase 1 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's planned 31 months is above that.
Counting every sponsor, half of 148 studies reached it within 16 months; a quarter within 5 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.